NextPharma Technologies Announces Senior Management Appointments
Surrey, UK, 4th March, 2008
NextPharma the leading European provider of product development, contract manufacturing and cold chain and logistics outsourcing services to the pharmaceutical and biotech industry, is pleased to announce the following appointment and changes to the responsibilities of its senior management team:
Jost Bunse has joined NextPharma as Management Director Cold Chain and Logistics Services, reporting to CEO, Bill Wedlake, NextPharma Technologies and is based in Waltrop, Germany. Jost has significant experience in logistics gained most recently at Miebach Consulting and Rhenus AG. He has previously worked at DHL and Phoenix a leading European pharmaceutical wholesaler. Jost Holds university qualifications in both Engineering and Economics.
Dr. Alfons Weische who has successfully managed NextPharma's Waltrop production facility for the last seven years in its transition from a big pharma manufacturing plant to a flexible outsourcing facility, as of today additionally will manage the NextPharma Bielefeld production facility. Detlef Bodmann will continue as General Manager of NextPharma's Göttingen and Berlin facilities the former of which has recently doubled in capacity following significant capital investment.
Bill Wedlake, CEO, NextPharma Technologies, commented: ' The volume of our logistics business has grown substantially over the last few years and we have become leaders in key areas such as temperature controlled storage and the storage of controlled substances. Jost's experience across our industry will significantly enhance our ability to match the demands of our customers providing innovative storage solutions to both our pharmaceutical and biotech customers. Alfons has demonstrated excellent commercial skills in developing our Waltrop facility and with storage growth across all of our German businesses we have taken this opportunity to balance management responsibilities. It is our objective to ensure that NextPharma remains at the forefront of timely, competitive, healthcare outsourcing solutions of the highest quality as restructuring in the pharma and biotech industry gathers pace'.
NextPharma develops, manufactures, packages, and distributes a broad range of products and formulations for its customers from tablets and capsules to antibiotics, hormones and controlled release medicines. It has an established leadership position in the high technology area of injectables manufacturing, with particular expertise in product development and manufacture of oncology medicines.
Contact:
Franck Latrille
Chief Executive Officer
NextPharma Technologies Holding Limited
Tel.: +44 (0) 1483 479 120
Notes to Editors:
About NextPharma
NextPharma Technologies, headquartered in the UK and founded in 2000, is world class provider of product development, contract manufacturing and distribution outsourcing services to the pharmaceutical, specialty pharmaceutical, generics and biotech industry.
It offers a broad range of services from early phase product development, through clinical trials supplies to high volume commercial manufacturing. NextPharma is a world leader in lyophilization, sterile fill-finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled substances. Its sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules.
NextPharma operates globally with seven product development centres, seven manufacturing plants and six storage and distribution sites across Europe and North America employing over 1,200 people. Across these locations NextPharma has built-up a strong track record in the development and manufacture of cytotoxics, hormones, antibiotics, pellets, sterile, solid, semi-solid, liquid and dry dosage forms, supplying customers in North America, Europe and Japan.
NextPharma has a customer base, which includes many of the world's leading pharmaceutical, specialty pharma and biotech companies.